Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 69.96
BTX's Cash to Debt is ranked higher than
73% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. BTX: 69.96 )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 69.96

Equity to Asset 0.20
BTX's Equity to Asset is ranked higher than
54% of the 968 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BTX: 0.20 )
BTX' s 10-Year Equity to Asset Range
Min: -45.87   Max: 0.99
Current: 0.2

-45.87
0.99
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
62% of the 575 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -3.25
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1248.45
BTX's Operating margin (%) is ranked higher than
57% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. BTX: -1248.45 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -1248.45

-9788.46
-116.83
Net-margin (%) -865.49
BTX's Net-margin (%) is ranked higher than
58% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. BTX: -865.49 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -865.49

-9471.15
-137.48
ROE (%) -299.82
BTX's ROE (%) is ranked higher than
51% of the 1154 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. BTX: -299.82 )
BTX' s 10-Year ROE (%) Range
Min: -2802.7   Max: -49.44
Current: -299.82

-2802.7
-49.44
ROA (%) -84.83
BTX's ROA (%) is ranked higher than
57% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. BTX: -84.83 )
BTX' s 10-Year ROA (%) Range
Min: -624.96   Max: -33.33
Current: -84.83

-624.96
-33.33
ROC (Joel Greenblatt) (%) -2247.02
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. BTX: -2247.02 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21242.11   Max: -800
Current: -2247.02

-21242.11
-800
Revenue Growth (3Y)(%) -3.90
BTX's Revenue Growth (3Y)(%) is ranked higher than
74% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 128.9
Current: -3.9

0
128.9
EBITDA Growth (3Y)(%) 63.40
BTX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -4.50 vs. BTX: 63.40 )
BTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.9   Max: 63.9
Current: 63.4

-48.9
63.9
EPS Growth (3Y)(%) 42.50
BTX's EPS Growth (3Y)(%) is ranked higher than
95% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BTX: 42.50 )
BTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.6   Max: 67.1
Current: 42.5

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 38.82
BTX's P/B is ranked higher than
54% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 6.64 vs. BTX: 38.82 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 38.82

5.65
83
P/S 49.55
BTX's P/S is ranked higher than
70% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. BTX: 49.55 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 49.55

4.83
124
EV-to-EBIT -5.71
BTX's EV-to-EBIT is ranked higher than
66% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: -5.71 )
BTX' s 10-Year EV-to-EBIT Range
Min: -71.7   Max: -1.1
Current: -5.71

-71.7
-1.1
Current Ratio 1.72
BTX's Current Ratio is ranked higher than
59% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. BTX: 1.72 )
BTX' s 10-Year Current Ratio Range
Min: 0.02   Max: 76
Current: 1.72

0.02
76
Quick Ratio 1.67
BTX's Quick Ratio is ranked higher than
61% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BTX: 1.67 )
BTX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 74
Current: 1.67

0.02
74
Days Inventory 86.36
BTX's Days Inventory is ranked higher than
91% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 86.36 )
BTX' s 10-Year Days Inventory Range
Min: 44.57   Max: 540.98
Current: 86.36

44.57
540.98
Days Sales Outstanding 70.40
BTX's Days Sales Outstanding is ranked higher than
80% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 116.17 vs. BTX: 70.40 )
BTX' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 70.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.29
BTX's Price/Median PS Value is ranked higher than
82% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. BTX: 1.29 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 15.45
Current: 1.29

0.14
15.45
Earnings Yield (Greenblatt) -17.50
BTX's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BTX: -17.50 )
BTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.7   Max: 0
Current: -17.5

-18.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated... Feb 24 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Feb 24 2015
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities Feb 17 2015
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities Feb 17 2015
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Feb 17 2015
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock Feb 10 2015
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Feb 06 2015
OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting Feb 06 2015
OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting Feb 06 2015
Asterias Biotherapeutics Prices Public Offering of Common Stock Feb 05 2015
Asterias Biotherapeutics Announces Public Offering of Common Stock Feb 04 2015
ESI BIO - A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific Feb 04 2015
LifeMap Sciences Announces Partnership with Advaita and Commercial Availability of Advaita’s... Feb 04 2015
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell... Jan 26 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Jan 26 2015
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell... Jan 26 2015
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of VarElect, the Next Generation... Jan 15 2015
BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors Jan 14 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Jan 12 2015
BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK